10299
|
ETCTN
|
A Phase I Study to Investigate the Safety of the Ubiquitin Activating Enzyme Inhibitor TAK-243 in Adult Solid Tumor and Lymphoma Patients
|
Adult CIRB - Early Phase Emphasis
|
Available to Open
|
|
10300
|
ETCTN
|
BLockade of PD-1 Added to Standard Therapy to target Measurable Residual Disease in Acute Myeloid Leukemia 1 (BLAST MRD AML-1): A Randomized Phase 2 Study of the Anti-PD-1 Antibody Pembrolizumab in Combination with Conventional Intensive Chemotherapy as Frontline Therapy in Patients with Acute Myeloid Leukemia
|
Adult CIRB - Early Phase Emphasis
|
Available to Open
|
|
10301
|
ETCTN
|
A Phase I and Randomized Phase II Trial of Radium-223 dichloride, M3814, & Avelumab in Advanced Metastatic Castrate-Resistant Prostate Cancer (mCRPC)
|
Adult CIRB - Early Phase Emphasis
|
Available to Open
|
|
10302
|
ETCTN
|
Phase II Trial of Radium-223 Dichloride in Combination with Paclitaxel in Patients with Bone Metastatic Breast Cancer
|
Adult CIRB - Early Phase Emphasis
|
Available to Open
|
|
10313
|
ETCTN
|
A phase IB and randomized open-label phase II study of M6620 in combination with carboplatin/gemcitabine/avelumab in patients with chemotherapy-naïve advanced non-small cell lung cancer of squamous cell histology
|
Adult CIRB - Early Phase Emphasis
|
Available to Open
|
|
10315
|
ETCTN
|
A Phase 2 Study of XL184 (Cabozantinib) in Combination with Nivolumab and Ipilimumab for the Treatment of Poorly Differentiated Neuroendocrine Carcinomas
|
Adult CIRB - Early Phase Emphasis
|
Available to Open
|
|
10317
|
ETCTN
|
A Pilot Study of Nivolumab in Combination with Decitabine and Venetoclax in TP53-mutated Acute Myeloid Leukemia
|
Adult CIRB - Early Phase Emphasis
|
Completed
|
|
10324
|
ETCTN
|
A Phase I/Ib Dose Escalation Study of Pegylated Liposomal Doxorubicin (PLD) With M3814 in Platinum-Resistant or Ineligible Ovarian and Related Cancers with Planned Expansions in High Grade Serous (HGSOC) and Low Grade Serous Ovarian Cancer (LGSOC)
|
Adult CIRB - Early Phase Emphasis
|
Available to Open
|
|
10327
|
ETCTN
|
A Phase 1 Trial of MLN0128 (sapanisertib) and CB-839 HCl (telaglenastat) in Advanced NSCLC Patients
|
Adult CIRB - Early Phase Emphasis
|
Available to Open
|
|
10329
|
ETCTN
|
Phase I Sequential Trial of Agents Against DNA Repair (STAR)
|
Adult CIRB - Early Phase Emphasis
|
Available to Open
|
|